Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Drug half life

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    606 result(s) found for: Drug half life. Displaying page 3 of 31.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2019-000324-17 Sponsor Protocol Number: GA18/118305 Start Date*: 2019-08-02
    Sponsor Name:University of Leeds
    Full Title: Amitriptyline at Low-dose and Titrated for Irritable Bowel Syndrome as Second-line Treatment (The ATLANTIS study): A Double-blind Placebo-controlled Trial
    Medical condition: Irritable Bowel Syndrome (IBS)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10023003 Irritable bowel syndrome PT
    20.1 10017947 - Gastrointestinal disorders 10023003 Irritable bowel syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2015-004207-22 Sponsor Protocol Number: CLCZ696B2319 Start Date*: 2017-04-06
    Sponsor Name:Novartis Pharma Services AG
    Full Title: Multicenter, open-label, study to evaluate safety, tolerability, pharmacokinetics and, pharmacodynamics of LCZ696 followed by a 52-week randomized, double-blind, parallel group, active-controlled s...
    Medical condition: Pediatric heart failure 1 month to <18 years old
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10019279 Heart failure LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed) NL (Ongoing) SE (Completed) NO (Completed) ES (Completed) GB (GB - no longer in EU/EEA) CZ (Completed) IT (Completed) FR (Completed) BG (Completed) PL (Completed) HU (Completed) HR (Completed) AT (Completed) PT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2020-004448-27 Sponsor Protocol Number: Uni-Koeln-4370 Start Date*: 2020-12-04
    Sponsor Name:University of Cologne
    Full Title: A Phase 1/2a Trial of the Inhaled Administration of the SARS-CoV-2-Neutralizing Monoclonal Antibody DZIF-10c in SARS-CoV-2-Infected and -Uninfected Individuals
    Medical condition: SARS-CoV-2 infection (only mild to moderate disease)
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10084272 SARS-CoV-2 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-004938-38 Sponsor Protocol Number: ADVANCE2020 Start Date*: 2021-12-08
    Sponsor Name:Frankfurter Institut für Klinische Krebsforschung IKF GmbH
    Full Title: ADVANCE: A phase II single-arm, open-label study of Atezolizumab and Derazantinib for patients with advanced intrahepatic cholangiocarcinoma with FGFR2 fusions/rearrangements
    Medical condition: Advanced non-resectable intrahepatic cholangiocarcinoma with positively confirmed FGFR2 fusion/rearrangements via NGS-Analysis
    Disease: Version SOC Term Classification Code Term Level
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008593 Cholangiocarcinoma PT
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008594 Cholangiocarcinoma non-resectable LLT
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073077 Intrahepatic cholangiocarcinoma LLT
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077846 Cholangiocarcinoma metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-003397-17 Sponsor Protocol Number: MCI-186-E04 Start Date*: 2009-01-23
    Sponsor Name:Mitsubishi Tanabe Pharma Corporation
    Full Title: A Phase IIa, multi-centre, randomised, double-blind, placebo controlled, clinical study investigating the safety, tolerability and pharmacokinetics of two different infusion doses over 72 hours of ...
    Medical condition: Acute ischemic stroke
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) FI (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-003906-26 Sponsor Protocol Number: ZEN003694-004 Start Date*: 2019-08-22
    Sponsor Name:Zenith Epigenetics Ltd.
    Full Title: A Phase 2 Study of ZEN003694 in Combination with Talazoparib in Patients with Triple-Negative Breast Cancer
    Medical condition: Triple Negative Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10071115 Node-negative breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-001896-63 Sponsor Protocol Number: E3810-A001-015 Start Date*: 2016-06-27
    Sponsor Name:Eisai Medical Research Inc.
    Full Title: An Ascending Bioavailability of a New Oral Suspension of E3810
    Medical condition: Bioavailability/Bioequivalence
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2009-009134-32 Sponsor Protocol Number: 2137/09 Start Date*: 2009-04-27
    Sponsor Name:North Bristol NHS Trust
    Full Title: Bristol Randomised Controlled Trial of Zoledronic Acid in Malignant Pleural disease(Pilot Study).
    Medical condition: Malignant pleural disease of all histological cell types. 50% patients in trial will have indwelling pleural catheters for management of breathlessness.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-011505-16 Sponsor Protocol Number: 3.0 Start Date*: 2010-01-21
    Sponsor Name:Medizinische Universität Wien,KIM I,Klinische Abteilung für Infektionen u.Tropenmedizin
    Full Title: Pharmacokinetics of intraperitoneal and intravenous fosfomycin in automated peritoneal dialysis patients without peritonitis
    Medical condition: A total of 8 patients with renal insufficiency and treatment with automated peritoneal dialysis (APD) will be enrolled into this study evaluating the pharmacokinetics of fosfomycin in this special ...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10034660 Peritoneal dialysis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2014-005615-17 Sponsor Protocol Number: RPL554-008-2014 Start Date*: 2015-04-22
    Sponsor Name:Verona Pharma plc
    Full Title: A Phase II, randomised, double blind, placebo controlled, seven way crossover study to assess the effect of single doses of RPL554 compared to salbutamol and placebo administered by nebuliser on lu...
    Medical condition: Patients with chronic asthma
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004855 10049106 Asthma chronic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2013-004555-21 Sponsor Protocol Number: CT-P103.2 Start Date*: 2014-04-07
    Sponsor Name:CELLTRION, Inc.
    Full Title: A Randomized, Controlled, Double-Blind, Parallel-Group, Phase 3 Study to Compare the Pharmacokinetics, Efficacy and Safety between CT-P10, Rituxan and MabThera in Patients with Rheumatoid Arthritis
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004870 10039075 Rheumatoid arthritis and associated conditions HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) LV (Completed) PT (Completed) DE (Completed) SK (Completed) HU (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2013-003829-29 Sponsor Protocol Number: EMR200637-002 Start Date*: 2014-10-27
    Sponsor Name:Symphogen A/S
    Full Title: Open-label, Randomized, Controlled, Multicenter Phase II Trial Investigating 2 Sym004 Doses versus Investigator`s Choice (Best Supportive Care, Capecitabine, 5-FU) in Subjects with Metastatic Color...
    Medical condition: Metastatic colorectal cancer with Acquired Resistance to Anti-EGFR Monoclonal Antibodies
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) BE (Completed) AT (Completed) HU (Completed) ES (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2019-004308-37 Sponsor Protocol Number: C19-28 Start Date*: 2021-01-20
    Sponsor Name:Institut National de la Santé et de la Recherche Médicale (INSERM)
    Full Title: Penetration of the innovative antibiotic gepotidacin into prostate and tonsillar tissue.
    Medical condition: Cohort A: Male patients with localized prostate cancer scheduled to undergo radical prostatectomy and patients with benign prostate hyperplasia scheduled to undergo simple prostatectomy Cohort B:...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-003441-13 Sponsor Protocol Number: D8480C00021 Start Date*: 2007-07-30
    Sponsor Name:AstraZeneca AB
    Full Title: A Two-part, Open-label, Multi-centre, Phase II Study in Patients with Advanced Solid Tumours, Consisting of a Randomised 2-period Crossover Protocol to Determine the Effect of Food upon the Pharmac...
    Medical condition: Patients with advanced solid tumour
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-003730-25 Sponsor Protocol Number: SBT20-102 Start Date*: 2017-02-14
    Sponsor Name:Stealth Bio Therapeutics Inc
    Full Title: A Two Part Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of SBT-020 in Patients with Early Stage Huntington’s Disease.
    Medical condition: Huntington's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10070668 Huntington's disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2018-001127-40 Sponsor Protocol Number: GO40554 Start Date*: 2019-05-10
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE I/II TRIAL OF MOSUNETUZUMAB (BTCT4465A) AS CONSOLIDATION THERAPY IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA FOLLOWING FIRST-LINE IMMUNOCHEMOTHERAPY AND AS THERAPY IN PATIENTS WITH PREVI...
    Medical condition: B-cell non-Hodgkin lymphoma (NHL)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2018-002278-33 Sponsor Protocol Number: PK_AB_NICU Start Date*: 2018-09-27
    Sponsor Name:Department of Clinical Pharmacology/Medical University of Vienna
    Full Title: Pharmacokinetics of antibiotics in cerebrospinal fluid of children with external ventricular drain
    Medical condition: We will obtain pharmacokinetic data of cefuroxime, vancomycin, gentamicin, ampicillin, linezolid, piperacillin/tazobactam and cefazolin in cerebrospinal fluid and plasma of children with external v...
    Disease:
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-002127-16 Sponsor Protocol Number: UCAB-CT-03 Start Date*: 2017-08-24
    Sponsor Name:Umecrine Cognition AB
    Full Title: A phase IIa study of GR3027 in patients with idiopathic hypersomnia (IH) involving an open-label part to assess safety, tolerability and pharmacokinetics (PK) of a single oral GR3027 dose in female...
    Medical condition: Idiopathic hypersomnia (IH)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10028714 Narcolepsy and hypersomnia HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed) DK (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2015-002136-40 Sponsor Protocol Number: 261203 Start Date*: Information not available in EudraCT
    Sponsor Name:Baxalta Innovations GmbH
    Full Title: Phase 3, prospective, multi-center, open label study to investigate safety, immunogenicity, and hemostatic efficacy of PEGylated Factor VIII (BAX 855) in previously untreated patients (PUPs) < 6 y...
    Medical condition: Severe hemophilia A (FVIII <1%)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10060612 Hemophilia A LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) BG (Prematurely Ended) ES (Completed) CZ (Prematurely Ended) AT (Completed) HU (Completed) DE (Completed) NL (Prematurely Ended) BE (Completed) NO (Completed) DK (Completed) FI (Completed) IT (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2018-001926-25 Sponsor Protocol Number: IM011046 Start Date*: 2019-02-11
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of BMS-986165 in Subjects with Moderate-to-Severe Plaque Psoriasis
    Medical condition: Moderate-to-Severe Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FR (Prematurely Ended) ES (Ongoing) DE (Completed) PL (Completed) Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jul 04 13:19:11 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA